BR112021021564A2 - Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv) - Google Patents
Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv)Info
- Publication number
- BR112021021564A2 BR112021021564A2 BR112021021564A BR112021021564A BR112021021564A2 BR 112021021564 A2 BR112021021564 A2 BR 112021021564A2 BR 112021021564 A BR112021021564 A BR 112021021564A BR 112021021564 A BR112021021564 A BR 112021021564A BR 112021021564 A2 BR112021021564 A2 BR 112021021564A2
- Authority
- BR
- Brazil
- Prior art keywords
- hbv
- virus
- indole
- innovative
- active against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv). a presente invenção se refere, em geral, a agentes antivirais inovadores. especificamente, a presente invenção se refere a compostos que podem inibir a(s) proteína(s) codificada(s) por vírus da hepatite b (hbv) ou interferir com a função do ciclo de replicação de hbv, composições que compreendem tais compostos, métodos para inibir replicação viral de hbv, métodos para tratar ou prevenir infecção por hbv e processos e intermediários para produzir os compostos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19172005 | 2019-04-30 | ||
EP19172398 | 2019-05-02 | ||
PCT/EP2020/061948 WO2020221826A1 (en) | 2019-04-30 | 2020-04-29 | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021021564A2 true BR112021021564A2 (pt) | 2022-01-04 |
Family
ID=70391142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021564A BR112021021564A2 (pt) | 2019-04-30 | 2020-04-29 | Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv) |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220306647A1 (pt) |
EP (1) | EP3962914A1 (pt) |
JP (1) | JP2022530522A (pt) |
KR (1) | KR20220004131A (pt) |
CN (1) | CN113767101A (pt) |
AU (1) | AU2020267015A1 (pt) |
BR (1) | BR112021021564A2 (pt) |
CA (1) | CA3138643A1 (pt) |
CL (1) | CL2021002799A1 (pt) |
CU (1) | CU20210088A7 (pt) |
EC (1) | ECSP21079317A (pt) |
IL (1) | IL287278A (pt) |
MX (1) | MX2021013085A (pt) |
SG (1) | SG11202111236UA (pt) |
TW (1) | TWI770501B (pt) |
UY (1) | UY38682A (pt) |
WO (1) | WO2020221826A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11976084B2 (en) | 2020-11-23 | 2024-05-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
WO2023137007A1 (en) | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
ATE354942T1 (de) | 1999-04-23 | 2006-03-15 | Extenday Ip Ltd | Foliebefestigungs- und verankerungsteil |
AU3009801A (en) | 1999-12-22 | 2001-07-03 | Bayer Aktiengesellschaft | Combinations of medicaments for treating viral diseases |
JP2008502741A (ja) | 2004-06-09 | 2008-01-31 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬 |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
US9399619B2 (en) | 2011-07-01 | 2016-07-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection |
WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
WO2013102655A1 (en) | 2012-01-06 | 2013-07-11 | Janssen R&D Ireland | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
US9096579B2 (en) * | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
JP2015533782A (ja) | 2012-08-28 | 2015-11-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 |
AU2013307328B2 (en) | 2012-08-28 | 2017-10-19 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
WO2014184328A1 (en) | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
PT2997019T (pt) | 2013-05-17 | 2018-11-21 | Janssen Sciences Ireland Uc | Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b |
PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
US10220034B2 (en) | 2013-10-18 | 2019-03-05 | Indiana University Research And Technology Corporation | Hepatitis B viral assembly effectors |
CA2928003A1 (en) | 2013-11-14 | 2015-05-21 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis b infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
LT3114128T (lt) | 2014-03-07 | 2019-03-25 | F. Hoffmann-La Roche Ag | Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai |
KR102363174B1 (ko) | 2014-03-13 | 2022-02-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 | B형 간염 코어 단백질 알로스테릭 조정제 |
CN104945395B (zh) | 2014-03-28 | 2018-01-23 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
CA2948580A1 (en) | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
MX2017001862A (es) | 2014-08-14 | 2017-05-15 | Hoffmann La Roche | Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b. |
CA2969557A1 (en) | 2014-12-02 | 2016-06-09 | Novira Therapeutics, Inc. | Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment |
JP6713465B2 (ja) | 2014-12-30 | 2020-06-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | B型肝炎感染症治療のための誘導体及び方法 |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
AU2016232353B2 (en) | 2015-03-16 | 2019-05-16 | F. Hoffmann-La Roche Ag | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor |
WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
EP3283472B1 (en) | 2015-04-17 | 2021-04-14 | Indiana University Research & Technology Corporation | Hepatitis b viral assembly effectors |
EP3292120B1 (en) | 2015-05-04 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
JP6598974B2 (ja) | 2015-07-21 | 2019-10-30 | エフ.ホフマン−ラ ロシュ アーゲー | B型肝炎ウイルス感染症の治療および予防のための新規な三環式4−ピリドン−3−カルボン酸誘導体 |
WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
TW201720802A (zh) | 2015-09-15 | 2017-06-16 | 艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
US10253030B2 (en) | 2015-11-04 | 2019-04-09 | Qilu Pharmaceutical Co., Ltd. | Crystal form, preparation method and intermediate of dihydropyrido ring compound |
WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | B型肝炎抗ウイルス剤 |
PL3441389T3 (pl) | 2016-04-06 | 2022-01-24 | Shanghai Zhimeng Biopharma, Inc. | Związek pirazolo-oksazolidynonowy przeciwko wirusowi zapalenia wątroby typu B |
EP3458455B1 (en) | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
EP3478683B1 (en) * | 2016-06-29 | 2021-07-21 | Novira Therapeutics Inc. | Diazepinone derivatives and their use in the treatment of hepatitis b infections |
JP7034133B2 (ja) | 2016-07-14 | 2022-03-11 | エフ.ホフマン-ラ ロシュ アーゲー | 感染性疾患の処置のためのカルボキシ 6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物 |
CN109476668B (zh) | 2016-07-14 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-三唑并[1,5-a]吡嗪化合物 |
WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
WO2018052967A1 (en) | 2016-09-13 | 2018-03-22 | Arbutus Biopharma, Inc. | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
SG11201908012SA (en) | 2017-03-02 | 2019-09-27 | Assembly Biosciences Inc | Cyclic sulfamide compounds and methods of using same |
WO2018172852A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
WO2018202155A1 (zh) | 2017-05-04 | 2018-11-08 | 上海长森药业有限公司 | 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途 |
JP2020528062A (ja) | 2017-07-27 | 2020-09-17 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用 |
TW201912153A (zh) | 2017-08-30 | 2019-04-01 | 加拿大商愛彼特生物製藥公司 | 用於治療b型肝炎的化合物、醫藥組合物及方法 |
US10759774B2 (en) | 2017-09-28 | 2020-09-01 | The Curators Of The University Of Missouri | Inhibitors of hepatitis B virus targeting capsid assembly |
CA3081386A1 (en) * | 2017-11-02 | 2019-05-09 | Aicuris Gmbh & Co. Kg | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
AR115131A1 (es) * | 2017-11-02 | 2020-12-02 | Aicuris Gmbh & Co Kg | Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb) |
-
2020
- 2020-04-29 MX MX2021013085A patent/MX2021013085A/es unknown
- 2020-04-29 CU CU2021000088A patent/CU20210088A7/es unknown
- 2020-04-29 SG SG11202111236UA patent/SG11202111236UA/en unknown
- 2020-04-29 CA CA3138643A patent/CA3138643A1/en active Pending
- 2020-04-29 WO PCT/EP2020/061948 patent/WO2020221826A1/en unknown
- 2020-04-29 KR KR1020217038545A patent/KR20220004131A/ko unknown
- 2020-04-29 JP JP2021564278A patent/JP2022530522A/ja active Pending
- 2020-04-29 US US17/607,605 patent/US20220306647A1/en active Pending
- 2020-04-29 AU AU2020267015A patent/AU2020267015A1/en not_active Abandoned
- 2020-04-29 CN CN202080032420.1A patent/CN113767101A/zh active Pending
- 2020-04-29 EP EP20720857.0A patent/EP3962914A1/en not_active Withdrawn
- 2020-04-29 BR BR112021021564A patent/BR112021021564A2/pt not_active IP Right Cessation
- 2020-04-30 TW TW109114654A patent/TWI770501B/zh active
- 2020-05-04 UY UY0001038682A patent/UY38682A/es unknown
-
2021
- 2021-10-14 IL IL287278A patent/IL287278A/en unknown
- 2021-10-25 CL CL2021002799A patent/CL2021002799A1/es unknown
- 2021-10-26 EC ECSENADI202179317A patent/ECSP21079317A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021013085A (es) | 2021-11-17 |
AU2020267015A1 (en) | 2021-12-23 |
CU20210088A7 (es) | 2022-06-06 |
US20220306647A1 (en) | 2022-09-29 |
SG11202111236UA (en) | 2021-11-29 |
EP3962914A1 (en) | 2022-03-09 |
KR20220004131A (ko) | 2022-01-11 |
ECSP21079317A (es) | 2021-11-30 |
TW202106687A (zh) | 2021-02-16 |
TWI770501B (zh) | 2022-07-11 |
IL287278A (en) | 2021-12-01 |
WO2020221826A1 (en) | 2020-11-05 |
UY38682A (es) | 2020-11-30 |
CN113767101A (zh) | 2021-12-07 |
CL2021002799A1 (es) | 2022-06-10 |
CA3138643A1 (en) | 2020-11-05 |
JP2022530522A (ja) | 2022-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550531A1 (en) | Novel, highly active pyrazolo-piperidine substituted indole2-carboxamides active against the hepatitis b virus (hbv) | |
PH12020550525A1 (en) | Novel, highly active amino-thiazole substituted indole-2carboxamides active against the hepatitis b virus (hbv) | |
CL2021001116A1 (es) | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) | |
UY38434A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) | |
CL2021001117A1 (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
BR112021021564A2 (pt) | Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv) | |
BR112021021580A2 (pt) | Fenil e piridil ureias inovadoras ativas contra o vírus da hepatite b (hbv) | |
UY38435A (es) | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
BR112021021652A2 (pt) | Oxalil piperazinas inovadoras ativas contra o vírus da hepatite b (hbv) | |
UY38439A (es) | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) | |
UY38681A (es) | Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
EA202192969A1 (ru) | Новые оксалилпиперазины, активные против вируса гепатита b (вгв) | |
EA202192967A1 (ru) | Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв) | |
PH12021550978A1 (en) | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) | |
EA202192968A1 (ru) | Новые фенил- и пиридилмочевины, активные против вируса гепатита b (вгв) | |
EA202192965A1 (ru) | Новые индолизин-2-карбоксамиды, активные против вируса гепатита b (вгв) | |
BR112022011212A2 (pt) | Derivados de heteroarildi-hidropirimidina e métodos de tratamento de infecções de hepatite b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2740 DE 11-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |